tiprankstipranks
Trending News
More News >

Solasia Pharma Reports Q1 2025 Financial Results with Increased Sales but Continued Losses

Story Highlights
Solasia Pharma Reports Q1 2025 Financial Results with Increased Sales but Continued Losses

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Solasia Pharma KK ( (JP:4597) ).

Solasia Pharma K.K. reported its consolidated financial results for the first quarter of 2025, showing a significant increase in sales to 25 million yen, up by 111% compared to the previous year. Despite the rise in sales, the company continued to report losses with an operating loss of 296 million yen. The financial forecast for the fiscal year ending December 31, 2025, anticipates sales of 1,300 million yen, indicating a substantial year-on-year growth, although the company expects to remain unprofitable with a projected loss of 650 million yen.

More about Solasia Pharma KK

Solasia Pharma K.K. is a pharmaceutical company listed on the Tokyo Growth exchange. The company focuses on developing and commercializing innovative oncology treatments, aiming to address unmet medical needs in the cancer treatment market.

Average Trading Volume: 4,341,935

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.02B

Find detailed analytics on 4597 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1